Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2015, Article ID 232607, 7 pages
Review Article

Orthotopic Heart Transplantation and Mechanical Circulatory Support in Cancer Survivors: Challenges and Outcomes

1Ottawa Cardiovascular Centre, Cardio-Oncology Survivorship Clinic, 1355 Bank Street, Suite 502, Ottawa, ON, Canada K1H 8K7
2Division of Oncology, Department of Medicine, University of Ottawa Cancer Centre, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6

Received 25 November 2014; Revised 5 April 2015; Accepted 5 April 2015

Academic Editor: Daniel Lenihan

Copyright © 2015 Nina Ghosh and John Hilton. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Chemotherapy-induced cardiomyopathy (CCMP) is a significant cause of morbidity and mortality. Compared to cardiomyopathy due to other causes, anthracycline-induced cardiomyopathy is associated with a worse survival. As cancer survival improves, patients with CCMP can be expected to comprise a significant proportion of patients who may require advanced therapies such as inotropic support, cardiac transplantation, or left ventricular assist device (LVAD). Distinct outcomes related to advanced therapies for end-stage heart failure in this patient population may arise due to unique demographic characteristics and comorbidities. We review recent literature regarding the characteristics of patients who have survived cancer undergoing orthotopic heart transplantation and mechanical circulatory support for end-stage heart failure. The challenges and outcomes of advanced therapies for heart failure related specifically to anthracycline-induced cardiomyopathy are emphasized.